我们检查了韩国儿童癌症青少年和青年 (AYA) 幸存者的白细胞相对端粒长度 (RTL)，并评估了白细胞 RTL 与多种因素的关联，包括恶性肿瘤类型、癌症治疗、年龄和慢性健康状况 (CHC) 。招募了 88 名 AYA 儿童癌症幸存者，中位随访时间为 73 个月。儿科癌症幸存者的 RTL 并不显着短于年龄匹配参考的预测值。诊断时的年龄和治疗持续时间均不会影响 RTL。在 43 名血液恶性肿瘤患者中，接受异基因造血干细胞移植 (HSCT) 的患者与未接受异体造血干细胞移植 (HSCT) 的患者相比，RTL 显着缩短 (p = 0.039)。在 15 名接受同种异体 HSCT 的患者中，发生 II 级或以上急性移植物抗宿主病 (GVHD) 的患者的 RTL 显着短于未发生的患者 (p = 0.012)。患有 II 级 CHC 的患者的 RTL 明显短于那些没有 CHC 或患有 I 级 CHC 的患者 (p = 0.001)。具有 ≥2 CHC 的幸存者也表现出较短的 RTL (p = 0.027)。总体而言，与年龄匹配的参考文献相比，儿科癌症幸存者的端粒长度相似。 HSCT 接受者和患有严重或多发 CHC 的患者的端粒较短。 GVHD 增加了 HSCT 受者的端粒磨损。

We examined the leukocyte relative telomere length (RTL) in Korean adolescent and young adult (AYA) survivors of childhood cancer and evaluated the association of leukocyte RTL with multiple factors, including malignancy type, cancer treatment, age, and chronic health conditions (CHCs). Eighty-eight AYA survivors of childhood cancer with a median follow-up period of 73 months were recruited. RTL in pediatric cancer survivors was not significantly shorter than the predicted value for age-matched references. Neither age at diagnosis nor duration of therapy influenced the RTL. Among the 43 patients with hematologic malignancies, those who underwent allogeneic hematopoietic stem cell transplantation (HSCT) showed a significant shortening of the RTL compared with those who did not (p = 0.039). Among the 15 patients who underwent allogeneic HSCT, those who developed acute graft-versus-host disease (GVHD) of grade II or higher had significantly shorter RTL than those who did not (p = 0.012). Patients with grade II CHCs had significantly shorter RTL than those without CHCs or with grade I CHCs (p = 0.001). Survivors with ≥2 CHCs also exhibited shorter RTL (p = 0.027). Overall, pediatric cancer survivors had similar telomere lengths compared to age-matched references. HSCT recipients and patients with severe or multiple CHCs had shorter telomeres. GVHD augmented telomere attrition in HSCT recipients.